Patients with gender dysphoria are offered cross-sex hormone therapy and sex reassignment surgery to achieve the transition between the sex assigned at birth and gender identity. According to international guidelines, cross-sex hormone therapy in transwomen should lead to a psychologically and physiologically healthy body with feminized serum hormone levels, resulting in suppression of spermatogenesis. However, in a recently published multi-center study, we discovered a high proportion of patients with male serum hormone levels and qualitatively intact spermatogenesis on the day of sex reassignment surgery. The objective of this study was to review the content of 11 publications that focus on the influence of cross-sex hormone therapy on testicular morphology. These publications were identified based on a PubMed search for the key words transgender/transsexual/gender dysphoria in male-to-female persons, cross-sex hormone therapy, and testicular tissues. Whereas three publications described a marked reduction of the spermatogenic level in all patients examined, eight publications reported inconsistent results. Histological analyses showed highly variable outcomes from qualitatively normal spermatogenesis and undisturbed Leydig/Sertoli cell morphology to full testicular regression with severe cellular damage and hyalinization. Explanations for these heterogeneous findings include insufficient cross-sex hormone therapy regarding dosage or duration. As complete spermatogenesis is associated with virilized serum hormone levels, these patients may face challenges especially after sex reassignment surgery in adjusting to the abruptly established hypogonadal state following removal of the testes. These findings also suggest that contraception should be discussed, and fertility preservation should be offered during/prior to cross-sex hormone therapy. There is a need for more individualized and better-controlled cross-sex hormone therapy and post-treatment regimens. Evidence-based guidelines for attending clinicians need to be established in order to deliver the most appropriate care.
INTRODUCTION
Gender identity is the personal identification and sense of being male or female, independent of the sex assigned at birth (Fabris et al., 2015) . Patients suffering from gender dysphoria (GD) experience the distressing scenario of incongruence between the gender assigned at birth and the personal identification. The etiology of GD remains hitherto unknown (Gooren, 2011) . Nonetheless, the urge to live in the opposite gender can be a distressing scenario and treatment requires hormonal, anatomical, legal, and psychosocial adaptations (Gooren et al., 2008; Kuyper & Wijsen, 2014) . Hence, patients with GD seek treatment and guidance from different experts and allied health professionals within the medical field.
In recent years, treatment of GD patients has become a topic of increasing medical relevance as more and more patients were referred for treatment (Judge et al., 2014) . Other studies confirmed that the prevalence has indeed increased over the past 50 years (Arcelus et al., 2015) . In a systematic review and metaanalysis, it was concluded that globally 4.6 in 100,000 individuals (6.8 for trans-women and 2.6 for trans-men) were transsexual and requested medical advice or treatment (Arcelus et al., 2015) .
The mean age at presentation appears to be similar throughout Europe with 36.3 years in Sweden (Dhejne et al., 2011) and 32.6 years in Ireland (Judge et al., 2014) . However, 61.9% of patients declared their age of self-diagnosis as being pre-pubertal (Byne et al., 2012) . While literature does not suggest that the age distribution at presentation is bimodal with a pre-pubertal and an older adult age group, a recent study suggests that the number of young patients at the time of presentation is indeed increasing (Judge et al., 2014) .
The complex care pathways of trans-individuals render the organization of medical service difficult (Arcelus et al., 2015) . When clinicians attempt to assess treatment protocols for the care of GD patients, two challenges become apparent: the absence of criteria whom to treat and the lack of consensus how to treat (Gorin-Lazard et al., 2012) . In Germany, the new guidelines of the Association of the Scientific Medical Societies (AWMF-guideline) are still in process. Up to now, the caring doctor has to rely on the international and European guidelines of the Endocrine Society and the World Professional Association of Transgender Health (WPATH). According to the European guidelines of the Endocrine Society, the treatment consists of diagnostic assessment, psychotherapy or counseling, real-life experience, cross-sex hormone therapy (CHT), and surgical therapy, which presents the final step in the process of phenotypical transition (Hembree et al., 2009) . A listing with recommendation from various bodies is presented in Table S1 . A more specific and applicable recommendation is provided by the WPATH (Version 7): This authority introduces four defined criteria to be fulfilled prior to CHT: 1. The subject should have a persistent, well-documented GD according to the Diagnostic and Statistical Manual of Mental Disorders V. 2. He/she should have the capacity to make a fully informed decision and to consent to treatment. 3. He/she should have the age of majority (in Germany 18 years of age). 4. Medical or mental health concerns must be reasonably controlled (WPATH, 2011) . Regarding criterium 3, it is important to note that some countries also allow treatment of children and young adolescents (using GnRH analogues), provided that they fulfill respective criteria and under the auspices of an ethics committee and/or legislation. This early treatment leads to a gradual regression of sex characteristic development, thereby prolonging the diagnostic phase as the body remains in a neutral early pubertal state (Fisher et al., 2016) . Since surgical intervention is only possible at the age of 18, data on the effects of these interventions on testicular tissues are not available.
To date, the procedure of CHT in GD patients is not fully standardized. Reasons for this include lack of controlled clinical trials on feminizing/masculinizing hormone regimens and the safety or efficacy in achieving physical transition (WPATH 2011 , Meriggiola & Berra, 2013 . The optimal steroid hormone treatment regime for transsexual subjects has also not yet been described (van Kesteren et al., 1997) . Recommendations for management are therefore based on expert opinion (Gooren et al., 2008) . To offer a personalized treatment, type of formulation, hormone dosage, and route of administration (oral, transdermal, or intramuscular) are variable (Wierckx et al., 2014b) . The existing variations in treatment modalities and the small number of subjects treated in each clinic render it difficult to collect valid data on the beneficial effects as well as unwanted side effects of CHT (Wierckx et al., 2014b) and sex-reassignment surgery (SRS).
CROSS-SEX HORMONE THERAPY (CHT)
For MtF patients, 'devirilization' using Cyproteron acetate (CPA) followed by 'feminization' using estrogens combined with anti-androgens is most commonly used (Gorin-Lazard et al., 2012) (Fig. 1) . CPA is a synthetic testosterone antagonist and acts as an anti-androgen and progestin. Persistently high serum levels of CPA lead to a down regulation of the hypothalamic gonadotropin releasing hormone (GnRH) activity and block gonadotropin release from the pituitary finally inhibiting testosterone release from testicular Leydig cells. Studies focusing the influence of hormonal treatments in prostate cancer patients revealed that GnRH agonists in biological men lead to a decrease of serum testosterone to castration levels within 2-3 weeks (Labrie et al., 2005) . Based on male contraceptive studies, however, GnRH analogues can suppress spermatogenesis only mildly, if used alone (Nieschlag et al., 2004) . In contrast, it has been demonstrated that CPA can be considered a potent progestin and suppresses spermatogenesis effectively also in humans (Fogh et al., 1979; Moltz et al., 1980; Wang & Yeung, 1980; Meriggiola et al., 1998) . Peripheral total and free testosterone and 5-adihydrotestosterone may reach very low levels leading to the desired effects on sexuality and androgen-dependent body functions (Turner et al., 2013) (Fig. 1) . Estrogen can be given orally as conjugated estrogens, or 17-b-estradiol, as transdermal estrogen, or parenteral estrogen esters (Hembree et al., 2009) .
Regarding treatment doses, the Endocrine Society recommends the prescription of either anti-androgens (Spironolactone 100-200 mg/day or Cyproterone acetate 50-100 mg/day) or GnRH agonists (3.75 mg s.c. monthly) for down regulation of the hyopthalamic-pituitary-adrenal axis. CPA is primarily used in Europe, whereas Spironolactone is favored in the USA. To achieve efficient suppression, both anti-androgenic drugs need to be taken on a regular basis at least several times per week if not daily. GnRH analogue therapy is expensive, but provides access to long-lasting formulations providing a more controlled long-lasting suppression (Meriggiola & Berra, 2013) . Female sex steroid replacement is reached by estrogen preparations (oral estradiol: 2.0-6.0 mg/day; transdermal estradiol: 0.1-0.4 mg twice weekly; parenteral estradiol: 5-20 mg i.m. every 2nd week) (Hembree et al., 2009) (Fig. 1) .
It is of utmost importance to screen all patients before starting CHT to exclude underlying diseases (i.e. clotting disorders, osteoporosis, obesity, osteoporosis, hypertension, breast cancer), which rule out estrogen treatment of any kind. Venous thromboembolism is the most serious complication and incidents have been reported for both transdermal and oral estradiol (Meriggiola & Gava, 2015) . If taken accordingly, the anti-androgens reduce endogenous testosterone levels. Serum testosterone levels should be lowered to the female range (<55 ng/dL), and serum estradiol should be increased to the mean serum level for pre-menopausal women (<200 pg/mL) (De Sutter, 2001; Hembree et al., 2009; Meriggiola & Berra, 2013) . With testosterone and free testosterone efficiently suppressed, sex hormone-binding globuline (SHBG) levels decrease. If anti-androgen medication is taken accordingly furthermore, SHBG levels will remain low thereafter. If patients take oral estrogen treatment SHBG will increase, in contrast to transdermal estrogen treatment (Wierckx et al. 2014b) . Extensive studies applying CHT confirmed that testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) are significantly suppressed (Giltay & Gooren, 2000; Fuss et al., 2015) . It was recommended to use LH as an indicator to monitor the adequacy of sex steroid administration (Gooren et al., 2008) . Under estrogen replacement, the synthesis and the release of prolactin from the pituitary is stimulated in a dose-and time-dependent fashion (Bunck et al., 2009 long CHT should be provided before SRS is a matter of debate. We performed a multi-center study revealing that some clinics advise their patients to terminate CHT several weeks prior to SRS, whereas other clinics advise continued treatment until the day of surgery (Schneider et al., 2015) . Reasons for discontinuation of CHT include the fear of increased bleeding during surgery or complications of wound healing in post-operative care (Hess et al., 2014) . Increased bleeding as a result of sex hormone exposure has no rational basis. In our study, we found a highly diverse outcome: More feminized hormonal levels (low testosterone, high estradiol levels) on the day of SRS were seen with continued CHT. In contrast, termination of CHT days or weeks prior to SRS leads to a partial or full masculine hormone profile (Schneider et al., 2015) . Several questions remain unanswered: Do different male or female hormone patterns on the day of SRS have any implications for the well-being of the individual patient prior or post-surgery? Is the potential surgical risk (i.e. bleeding risk, pharmacological interference) for terminating SRS balanced against the sudden withdrawal of sex steroids following SRS?
PHYSIOLOGICAL EFFECTS INDUCED BY CHT AND SEX REASSIGNMENT
Physical changes that may occur in the first 3-6 months of CHT include redistribution of body fat mass decreased libido, oiliness of skin, breast tissue growth, and reduction of facial and body hair. Maximum breast development is generally achieved 2 years after initiation of hormone treatment (Hembree et al., 2009) . A decrease in LH and FSH in combination with the exogenous steroid levels during CHT leads to weight gain, gynecomastia, and lethargy, as well as a decrease in sexual interests and sexual fantasies (Meriggiola et al., 1998) . Total bodyweight remained unchanged for MtF transsexuals, although they experienced an increase in total body fat mass and a decrease in total body lean mass (n = 32) (Wierckx et al., 2014b) . Increased serum leptin levels may influence eating habits in MtF subjects under CHT (Elbers et al., 1997) . The majority of male-to-female transsexuals reported a decrease in sexual desire after treatment (Wierckx et al., 2011 (Wierckx et al., , 2014a . A decline in serum testosterone levels or testosterone action together with increased SHBG and high estradiol levels may be responsible for this low sexual desire (Wierckx et al., 2014b) .
EFFECT OF CHT ON TESTICULAR MORPHOLOGY
Anticipated effects of CHT on the testis can be derived from male contraception studies demonstrating that gonadotropin suppression leads to spermatogenic suppression (Bremner, 2012) . Importantly, this effect on spermatogenesis was fully reversible in biological men with sperm recovery to the thresholds of 20 million/mL within 3.4 months (Liu et al., 2006) . With regard to transgender patients, these data suggest that discontinuation of anti-androgen treatment prior to SRS will result in an increase of intra-testicular and serum testosterone levels and a re-initiation of spermatogenesis. Figure 1 Requirements, treatment strategies, and targets of cross-sex hormone treatment of patients with gender dysphoria. Abbreviations stand for: GnRH: Gonadotropin releasing hormone, LH: Luteinizing hormone, FSH: Follicle-stimulating hormone, SCO: Sertoli cell only.
In addition, elevated peripheral estrogen levels have diverse effects on male reproductive organs. Changes were observed regarding the rete testis, efferent ducts, and to a lesser degree, the epididymis and Leydig cells (Sapino et al., 1987) . With regard to the germ cells, exogenous doses of 20 lg/day of ethinylestradiol had no negative effect on sperm motility and sperm density, whereas higher doses (60 lg/day) lead to a reduction of sperm motility after a few days. After 2 weeks, also sperm counts were affected by high doses of estrogens (Lubbert et al., 1992) .
The actual influence of CHT on testicular morphology in male-to-female (MtF) GD patients has been described in 11 publications to date with very different outcomes (Table 1) . While some patients showed severe involution of spermatogenesis as well as Leydig cells, other patients maintained qualitatively complete spermatogenesis with normal Leydig cell abundance (Payer et al., 1979; Thiagaraj et al., 1987; Venizelos & Paradinas, 1988) .
More specifically, Thiagaraj et al. (1987) reported that three of 10 patients did not respond to CHT, based on unchanged testicular volumes and testicular histology (Thiagaraj et al., 1987) . This contrasts to a study in which the testes of four patients were analyzed and showed primarily Sertoli-cell only tubules with occasional spermatogonia in individual seminiferous tubules (Lu & Steinberger, 1978) . In line with this, Schulze (1988) reported about 12 subjects who showed a uniform and strong testicular involution. Complete spermatogenic depletion was shown as no differentiating germ cells were detected, and the seminiferous tubules contained exclusively Sertoli cells and spermatogonia. The tubules, were decreased in diameter, showed no lumen, and were surrounded by an extensively thickened lamina propria. Finally, Leydig cells were not detected in these testicular tissues (Schulze, 1988) . This latter finding led the author to suggest that the treatment causes mature Leydig cells to de-differentiate into Leydig cell precursor cells with a fibroblast-like appearance (Schulze, 1988) . Functionally, androgen production of Leydig cells may be altered by estrogens via two different mechanisms. Estrogens may have a direct effect on Leydig cells or may act indirectly via suppression of gonadotropins. The latter effect is likely long term and requires higher doses (Rodriguez-Rigau et al., 1977) .
In our own study, we analyzed testicular tissues of 108 patients. We confirmed the variability of the spermatogenic Histology revealed a highly heterogeneous picture with 24% patients with normal spermatogenesis irrespective of the treatment strategy. Only patients that did not discontinue hormonal treatment showed feminized blood levels on the day of SRS and the lowest ITT levels.
876 Andrology, 2017, 5, 873-880 involution under CHT based on differing testicular weights and corresponding degrees of germ cell depletion (Schneider et al., 2015) . In 24% of the patients, we found qualitatively complete spermatogenesis on the day of SRS. The majority of patients, however, showed an obvious involution down to a Sertoli-cellonly phenotype and fully hyalinized seminiferous tubules (tubular shadows). The status of spermatogenesis, in terms of the most advanced germ cell type, did not correlate to the levels of intratesticular testosterone. As testicular tissues were obtained from three different clinics with distinct treatment regimens prior to SRS, we compared the three patient groups that either discontinued CHT a couple of weeks prior to SRS or underwent continuous CHT. Only those patients with a continuous CHT showed feminized blood levels and low intratesticular testosterone levels on the day of SRS. Intriguingly though, these data were independent of the degree of the histologically detectable spermatogenic involution indicating that the endocrine process can be reverted to a male pattern in just a few weeks, whereas the spermatogenic involution will persist for a longer period (Schneider et al., 2015) (Table 1) . Importantly, as the testicular volume should decrease by 25% within the first year of therapy due to depletion of germ cells, this decline in testis weight represents a valid readout of the efficiency of spermatogenic suppression (Mayerhofer, 2013; Schneider et al., 2015) .
In children treated with GnRH agonists, a decrease of testicular volume in 43 of 49 patients was found (Schagen et al., 2016) . The proliferation of the pre-pubertal testis is caused by gonadotropin secretion. Plant et al. demonstrated in pre-pubertal Rhesus monkeys that spermatogonial proliferation, the increase of Sertoli cells, the number and morphology of Leydig cells is gonadotropin dependent and consequently so is the testosterone secretion. Hence, suppressing gonadotropins early in the development might hinder the preparation of the adult testis (Plant et al., 2005) .
SEX-REASSIGNMENT SURGERY AND POSTOPERATIVE CARE
Presently, the surgeon performing SRS is not obliged to control that a feminized serum hormone profile has been achieved by CHT and that spermatogenesis is regressed. This could be easily assessed by palpation to confirm the presence of small testes. Unger (2014) suggests that surgeons should choose their patients carefully and with appropriate scrutiny (Unger, 2014) . In Germany, patients responded with subjective satisfaction to SRS and appreciated the good operative results indicating that SRS has a positive effect on the post-surgical life (Hess et al., 2014) . Following SRS, including orchiectomy, hormonal therapy must be continued according to guidelines (Hembree et al., 2009) . However, sex hormone levels are rarely monitored post-surgically albeit it is important to maintain sex steroid-dependent physiological functions (Meriggiola & Berra, 2013) . This however, is of particular importance as surgeons in some clinics in Germany (gynecologist, urologist, reconstructive surgeon), who have not been part of the treatment prior to surgery, advice patients to stop CHT prior to SRS in fear of complications during surgery as mentioned above.
In particular in these cases, adequate care should include a personalized sex hormone replacement therapy for the abruptly gonadectomized individual. This may include temporal substitution with male sex steroids to provide a slow and steady transition as well as testing of various sex-steroid replacement regimens leading to best satisfaction of the individual. Further research is needed to correlate endocrine and physiological features in GD individuals to optimize pre-and post-surgical care.
PSYCHOLOGICAL EFFECTS OF SEX REASSIGNMENT
No significant psychopathologies have been reported in preand post-operative assessments of GD patients under CHT (Heylens et al., 2014) . However, primarily after initiation of CHT, the majority of patients reported to be in better mood, they were happier, and less anxious (Heylens et al., 2014) . Also, they appeared more self-confident and encountered a better bodyrelated experience, indicating a less distorted self-image (Fisher et al., 2014; Heylens et al., 2014) . The most important effect resulted from the confirmation of the diagnosis and the initiation of hormone therapy (Heylens et al., 2014) .
However, a Swedish study showed that GD patients after SRS have considerably higher risks of mortality, suicidal behavior, and psychiatric morbidity compared to the general population (Dhejne et al., 2011) . This study suggests that sex reassignment, although alleviating GD, may not suffice as treatment for transsexualism. Instead, improved psychiatric and somatic care after sex reassignment for this patient group appear to be necessary (Dhejne et al., 2011) . In contrast, a German study concluded that the suicide rate was not increased compared to the general population (Eicher, 1992) . To the best of our knowledge, no study correlated sex hormone status or spermatogenic level with psychological and physiological outcomes during CHT, neither before nor after SRS.
SIDE EFFECTS OF CHT AND CONTROL EXAMINATIONS
It is recommended that transgender individuals undergoing CHT are checked initially every 3 months and then at least annually for hematological changes liver and kidney function and blood pressure during the first year and then every 6-12 months from the second year onwards (Meriggiola & Berra, 2013) . No deaths, cardiovascular events, osteoporotic fractures, venous thromboses, or pulmonary embolisms were observed in trans-women (Wierckx et al., 2014b) .
We found a pronounced increase in prolactin in male-tofemale subjects on the day of SRS (Schneider et al., 2015) . The elevated levels of prolactin (greater than 1000 mU/L) were associated with high doses of estrogens and advanced age at the start of the treatment (Asscheman et al., 1988) . Prolactinomas in male-to-female transsexual subjects due to high and conventional doses of estrogens have been reported (Asscheman et al., 1988; Cunha et al., 2015) , but the clinical relevance of increased prolactin levels during CHT remains unknown (Wierckx et al., 2014b) . Dual-energy X-ray absorptiometry is recommended in patients at risk for developing osteoporosis (i.e. family history) and at an advanced age (>60 years; (Meriggiola & Berra, 2013) . It was shown that 20.5% of the follow-up patients suffered from osteopenia and 7.7% were diagnosed with osteoporosis (Judge et al., 2014) . Estrogens (in combination with anti-androgens) decrease bone turnover, with a subsequent increase in bone marrow density and a decrease in serum Insulin like growth hormone 1 (van Kesteren et al., 1996) . Bone loss may occur despite estrogen supplementation due to the effects of anti-androgens, which lower testosterone serum concentrations and induce hypogonadism (Meriggiola & Berra, 2013) . Although there is no evidence that prostate cancer is more frequent in GD patients, the prostate should be monitored from the age of 50 onwards, as generally recommended for men (Gooren & Morgentaler, 2014) .
PROBLEMATIC ASPECTS IN RELATION TO SEX REASSIGNMENT TREATMENT
It appears obvious that maintenance of steroid hormone levels in the physiological range of the desired sex should be achieved in individuals with GD prior and post-SRS (Meriggiola et al., 2010) . The Endocrine Society recommends monitoring patients every 3 months during the first year of therapy and once or twice yearly thereafter (Hembree et al., 2009) . For CHT to be well tolerated, it is necessary to perform the hormonal administration in a highly individualized scheme in terms of timing, doses and modes of administration (Meriggiola & Berra, 2013) . Treatment can be considered successful if it relieves distress or facilitates substantial improvement in function and well-being of the patient (Byne et al., 2012) .
The hormonal therapy in MtF subjects lasts 6.0 years on average (Wierckx et al., 2014b) . Based on expert opinion, however, patients tend to follow their self-controlled individual regimes as estrogen-and androgen-formulations are easily available via the Internet, over the counter, without prescription in certain settings, and through veterinary supply (Byne et al., 2012) . However, subjects should be strongly discouraged from inducing supra-physiological hormone levels due to serious side effects (Meriggiola & Berra, 2013) . According to Leinung et al. (2013) , 9.8% of male-to-female transsexuals started hormonal therapy without prescriptions from a physician and nearly all admitted of initiating hormonal therapy without medical supervision (Leinung et al., 2013) . This is surprising as one of the three inclusion criteria of the WPATH for GD therapy is the ability to take hormones in a responsible manner (WPATH, 2011) .
Before starting CHT, it is indicated to inform the patient about contraceptive needs during CHT. Also, patients should be counseled about options of fertility preservation by cryopreservation of semen (Byne et al., 2012) . The desire to reproduce and raise children is an inadequately studied field in transsexual persons. It is known that masturbation can be emotionally challenging and cryopreservation might also be a financial burden for GD patients (De Sutter, 2001; Wierckx et al., 2012 ). Yet, cryopreservation of spermatozoa, which can be used later for insemination -in vitro fertilization (IVF) or intracytoplasmatic sperm injection (ICSI), is a validated approach (T'Sjoen et al., 2013). Moreover, spermatozoa from testicular tissue can be preserved after retrieval by biopsy or-when the involution is not fully complete -from the dissected testes or epididymides following SRS, as only few spermatozoa are needed to attain fertilization and pregnancy through ICSI with cryopreserved testicular or epididymal spermatozoa (T'Sjoen et al., 2013) .
Moreover, transgender medicine is rarely part of medical school curricula (Safer & Pearce, 2013) , even though introduction of modules early during clinical education was suggested (Wylie et al., 2016) . One of the consequences of non-adequate staff training is that individuals suffering from GD are ignored and often dismissed in healthcare settings (Fabris et al. 2015 ). An interdisciplinary approach including several specialists will be mandatory for the adequate care of these patients (Fig. 1) .
CONCLUSION
Adequate hormonal treatment in male-to-female GD patients is undoubtedly beneficial and is associated with higher social, emotional, and mental quality of life scores (Gorin-Lazard et al., 2012) . However, the treatment of transsexual subjects is a challenging task. In collaboration with mental health professionals and surgeons, endocrinologists are asked to confirm the diagnosis and individually adjust hormonal treatments with the goal to adequately suppress endogenous sex hormone levels and to achieve and maintain hormone characteristics of the desired gender (Meriggiola et al., 2010) .
Sex reassignment therapy with CHT and SRS has a major impact on the psychology and physiology of individual patients. Research has shown that patients on the day of SRS are very different regarding hormonal status ranging from feminized to virilized sex hormone levels. In addition, the status of spermatogenesis ranges from intact spermatogenesis to complete atrophy, irrespective of sex hormone levels. Patients with virilized hormone levels and complete spermatogenesis could face problems adjusting after SRS due to the sudden withdrawal of testosterone. Patients from our own studies were highly variable at the time of SRS.
Based on the literature review and based on our own research, we recommend a sufficient anti-androgen therapy with CPA (100 mg daily) or GnRH analogues (3.75 mg monthly) in addition to favorable estrogen replacement therapy depending on the individual patient until the day of SRS and under close supervision of an experienced endocrinologist (Fig. 1) . Furthermore, estrogen treatment should be continued after SRS to prevent hypogonadism (Meriggiola et al. 2015) . In order to achieve a better standardization of treatment results, including the effect on spermatogenesis, a higher standardization of treatment protocols appears to be essential. We therefore propose monitoring of sex hormones (LH, FSH, testosterone, free testosterone, prolactin, estrogen, SHBG) during CHT as well as after SRS and monitoring of the testicular status (i.e. testicular weight, ejaculate examination) prior to SRS on an annual basis. Based on these parameters, treatment protocols can then be further refined in the future studies. We also suggest discussing fertility options and contraceptive strategies during the course of CHT until SRS. Finally, health personal needs to be trained to improve and develop individual care strategies for transgender patients.
